Technology & Innovation

DB HiTek Completes World-First 8-Inch SiC MOSFET Qualification

Image
DB HiTek Completes World-First 8-Inch SiC MOSFET Qualification

Seoul – September 13, 2026 -- DB HiTek has completed reliability qualification for its 8-inch (200mm) 1,200V silicon carbide (SiC) MOSFET manufacturing process, establishing what the company calls the world's first complete foundry production flow for 8-inch SiC power semiconductors. Mass production is targeted for 2027.

DB HiTek Clears Reliability Tests for 1,200V SiC MOSFETs on 8-Inch Wafers

Image
DB HiTek Clears Reliability Tests for 1,200V SiC MOSFETs on 8-Inch Wafers

Seoul – September 13, 2026 -- DB HiTek has completed reliability qualification testing for its 1,200V silicon carbide (SiC) MOSFET process on 8-inch (200mm) wafers, establishing what the company calls the world's first full-service process for 8-inch SiC semiconductor production.

DB HiTek targets 2027 mass production launch for 8-inch SiC wafers

The South Korean specialty foundry plans to open the process to existing customers in the third quarter of this year and extend availability to all clients starting in the second quarter of 2027. The move addresses a shift among major global chipmakers from 6-inch to 8-inch SiC wafers to cut production costs and improve manufacturing efficiency, a transition driven by SiC's superior performance over silicon in high-voltage, high-temperature applications used in electric vehicles, renewable energy systems and industrial power equipment.

Shenzhen Expo to Debut TGV Glass Substrate Line, AI+AR Glasses Zone

Shenzhen – September 11, 2026 -- C-TOUCH & DISPLAY SHENZHEN 2026 will occupy 180,000 square meters across four halls at the Shenzhen World Exhibition & Convention Center from October 27-29, drawing over 3,600 exhibitors and 170,000 professional visitors, including more than 5,000 overseas buyers.

The 29th edition of the show introduces three dedicated technology zones targeting emerging display-photonics convergence, according to organizer RX Kuozhan, a joint venture between Reed Exhibitions and Kuozhan Exhibition Services Shanghai established in 2015.

LG Energy Solution, Seoul National University Crack LMR Battery Gas Problem

Image
LG Energy Solution, Seoul National University Crack LMR Battery Gas Problem

Seoul – September 10, 2026 -- LG Energy Solution and Seoul National University have developed a voltage-control method that suppresses gas evolution in lithium manganese-rich (LMR) batteries, clearing a major barrier to commercializing the cobalt-free chemistry in large-format EV cells.

The joint research team, led by Professor Jongwoo Lim of Seoul National University's Department of Chemistry, published its findings in Nature Communications on September 7 Seoul time. LG Energy Solution announced the results the same day.

Optimized 40 Ah cells retained 92.2% of initial energy after 883 cycles

Researchers applied the new operating protocol to 40 Ah-class large-format LMR cells, which held onto 92.2 percent of their original energy capacity following 883 charge-discharge cycles. The result demonstrates cycle-life stability sufficient to move LMR materials beyond small-format applications and into large EV battery packs.

TCL CSOT Debuts IJP OLED Lineup, Cites $156 Billion Display Market by 2030

Image
TCL CSOT Debuts IJP OLED Lineup, Cites $156 Billion Display Market by 2030

Shanghai -- September 01, 2026 -- TCL CSOT opened its exhibition at the Display Innovation China Expo 2026 in Shanghai on Aug. 31, presenting a lineup of OLED, Micro LED and automotive display technologies. The company said its inkjet-printed (IJP) OLED technology has already reached mass production in the professional display sector and is now being validated with device brands for consumer laptops and monitors. Executives cited industry data projecting the global display market to grow from $123 billion in 2022 to $156 billion by 2030.

Philips Wins FDA Clearance for Reusable SpO₂ Sensor Built to Hold Accuracy Across Skin Tones

Image
Philips Wins FDA Clearance for Reusable SpO₂ Sensor Built to Hold Accuracy Across Skin Tones

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, a pulse oximetry device built around internal optical refinements that improve signal quality. In desaturation testing, the sensor posted an accuracy result nearly twice as tight as the level recommended by ISO and recognized by the FDA. It also held accuracy within half a percentage point between light and dark skin pigmentation groups tested. The clearance extends Philips' broader pulse oximetry portfolio and follows a validation program built specifically around performance across diverse patient populations.

Philips Adds Alturion to Ultrasound Line, Targets High-Volume Clinical Workflows

Image
Philips Adds Alturion to Ultrasound Line, Targets High-Volume Clinical Workflows

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has launched Alturion, a new ultrasound system built for departments that run high patient volumes across varied exam types. The system pairs AI-powered workflow tools with imaging hardware designed to hold up across shift changes and multiple users. Alturion has received FDA 510(k) clearance and CE mark certification, making it available now in the U.S. and Europe. Philips positions the launch as an expansion of its ultrasound portfolio rather than a standalone product, built to share transducers and interface design with existing systems already in clinical use.

HD Advanced Technologies and PHENOGY Build Sodium-Ion Battery Manufacturing Base in Germany

Image
HD Advanced Technologies and PHENOGY Build Sodium-Ion Battery Manufacturing Base in Germany

SHERIDAN, WYOMING -- July 22, 2026 -- HD Advanced Technologies GmbH (HDAT), a wholly owned subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), has signed a two-part industrial partnership with Swiss battery developer PHENOGY AG. HDAT will take over contract manufacturing of PHENOGY's sodium-ion energy storage systems, covering everything from procurement to installation and maintenance. The two companies are also preparing a joint venture to develop and mass-produce sodium-ion battery cells, combining PHENOGY's cell chemistry with a HEIDELBERG printing process. The goal is a European-based supply chain for battery storage that does not depend on manufacturing capacity outside the region.

HEIDELBERG Adds ChromaStar Dispensing Line to Cut Spot Color Bottlenecks in Packaging Printing

Image
HEIDELBERG Adds ChromaStar Dispensing Line to Cut Spot Color Bottlenecks in Packaging Printing

SHERIDAN, WYOMING -- July 22, 2026 -- Heidelberger Druckmaschinen AG (HEIDELBERG) has introduced the ChromaStar series, a modular ink dispensing platform built to automate spot color production directly inside print shops. The system targets a persistent operational problem in packaging printing: manual, unstandardized spot color mixing that slows turnaround and ties up skilled staff. Four models — X, S, M, and P — scale from entry-level manual batch preparation to fully automated, high-volume industrial dispensing. HEIDELBERG frames the launch as an expansion of its Lifecycle consumables business and its role as a system integrator for packaging printers.

Roche's Divarasib Beats Approved KRAS G12C Drugs in Head-to-Head Lung Cancer Trial

Image
Roche's Divarasib Beats Approved KRAS G12C Drugs in Head-to-Head Lung Cancer Trial

SHERIDAN, WYOMING -- July 08, 2026 -- Roche announced positive results from the phase III Krascendo 1 study, showing that its investigational KRAS G12C inhibitor divarasib outperformed the approved first-generation inhibitors sotorasib and adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer. The study met both its primary and key secondary endpoints, with divarasib delivering statistically significant improvements in progression-free survival and overall survival. Roche plans to submit the data to health authorities and present full results at an upcoming medical meeting. The company positions the results as evidence that divarasib could become a new treatment standard for this genetically defined subgroup of lung cancer patients.